Home » Newsletters » BioWorld Science

BioWorld Science

July 27, 2012

View Archived Issues

Biokine Therapeutics drug receives orphan drug status for use in stem cell mobilization

New model of abdominal wall allotransplantation developed in China

Novavax reports on clinical programs for VLP vaccine candidates

Two new photosensitizers show promise for use in cancer

Avagacestat evaluated in Asian subjects

Purdue Pharma discloses novel sodium channel blockers

Scientists at Avidin present new anticancer agents

Protalex reports on PRTX-100 trial in RA

SuppreMol enters agreement to develop SM-401 for rheumatoid arthritis

Novel antibacterial vaccines patented by Novartis

U.S. study uncovers basis for LOAD locus heterogeneity in the Amish

Proteostasis Therapeutics expands collaboration with Scripps Research Institute

IRM designs new farnesoid X receptor agonists

Pfizer files application for Prevenar 13

Biodel awarded NIH grant to develop concentrated ultrarapid-acting insulin

Novel agents for migraine divulged

Group at Abbott prepares new IL-1 alpha-binding proteins

Otsuka receives FDA complete response letter regarding new aripiprazole formulation

U.S. researchers report novel glucagon receptor agonists

Alimera obtains marketing approval in Germany for Iluvien

Kyowa Hakko Kirin set to launch Apokyn in Japan

FDA approves Vascepa to reduce triglyceride levels in adults with severe hypertriglyceridemia

Eisai obtains European approval for perampanel

FDA advisory committee recommends approval of Genentech drug for DME

Quattrovac approved in Japan

Luitpold receives FDA complete response letter for Injectafer

FDA approves novel formulation of prednisone for rheumatoid arthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...